Exchange: NASDAQ·Updated 10:16 AM EDT
RYTM logo

RYTM Rhythm Pharmaceuticals Inc.

$105.38
$0.04
(0.04%)
Today
Reported EarningsAug 4
Mkt Cap$7.26B
Vol20,492.00

About RYTM

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.
37

Bearish Sentiment

How do you feel about RYTM?

Advertisement|Remove ads.